New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 27, 2022 - Amneal announced the FDA approval of Fylnetra (pegfilgrastim-pbbk), biosimilar to Amgen’s Neulasta® (pegfilgrastim).
Download PDF
Return to publications
